Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results Septerna (Nasdaq: SEPN) reported Q4 and full-year 2025 results and highlighted pipeline progress, including positive Phase 1 data for SEP-631 and IND-enabling completion for SEP-479. Cash totaled $548.7M at year-end, and management expects runway to support operations at least into 2029.SEP-631 showed favorable safety, once-daily PK, and dose-dependent PD with near-complete inhibition at higher doses; Phase 2b in CSU planned in H2 2026.

#SEPN Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/SEPN/septerna-highl...

Trade Alerts, Monday January 12, 2026 – Crystal Equity Research

Small-cap stocks with declining money flow, Mon Jan 12th - #TLS #STKL #SEPN #RBBN #PRQR #OM #NWL #NAGE #MDWD #IART #HNRG #GEMI #FCCO #EQ #DOMO #CLNN #BTBT #AUTL #SI #OPFI #JBI #CPF #CDRE #AHT - More: crystalequityresearch.com/trade-alerts... - #smallcap

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE

#SEPN Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/SEPN/septerna-highl...

Worldline to Expand Network Based on Scion Technology Global payments provider Worldline plans to expand its Secure EFTPOS Network (SEPN) to further industries and partners, aiming to strengthen the cyber resilience of the entire payments ecosystem and provide companies with a secure digital infrastructure for cashless transactions. Behind this initiative is technology developed in Zurich that also plays a key role in Switzerland’s SIC payment system.

Worldline to Expand Network Based on Scion Technology: Global payments provider Worldline plans to expand its Secure EFTPOS Network (SEPN) to further industries and partners, aiming to strengthen the cyber resilience of the entire payments ecosystem and provide companies with a… #Worldline #SEPN

Worldline will auf Scion-Technologie basierendes Netzwerk ausbauen Die im Markt für Zahlungsverkehr tätige Worldline will mit der Expansion ihrer Netzwerkes SEPN die Cyber-Resilienz des gesamten Zahlungsökosystems stärken und Unternehmen eine sichere digitale Infrastruktur für bargeldlose Zahlungen zur Verfügung stellen. Dahinter steckt eine Technologie aus Zürich, die auch für das Schweizer Zahlungssystem SIC relevant ist.

Worldline will auf Scion-Technologie basierendes Netzwerk ausbauen: Die im Markt für Zahlungsverkehr tätige Worldline will mit der Expansion ihrer Netzwerkes SEPN die Cyber-Resilienz des gesamten Zahlungsökosystems stärken und Unternehmen eine sichere digitale Infrastruktur für… #Worldline #SEPN

Worldline will auf Scion-Technologie basierendes Netzwerk ausbauen Die im Markt für Zahlungsverkehr tätige Worldline will mit der Expansion ihrer Netzwerkes SEPN die Cyber-Resilienz des gesamten Zahlungsökosystems stärken und Unternehmen eine sichere digitale Infrastruktur für bargeldlose Zahlungen zur Verfügung stellen. Dahinter steckt eine Technologie aus Zürich, die auch für das Schweizer Zahlungssystem SIC relevant ist.

Worldline will auf Scion-Technologie basierendes Netzwerk ausbauen: Die im Markt für Zahlungsverkehr tätige Worldline will mit der Expansion ihrer Netzwerkes SEPN die Cyber-Resilienz des gesamten Zahlungsökosystems stärken und Unternehmen eine sichere digitale Infrastruktur für… #Worldline #SEPN

Leading Indicators, Thursday September 25, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Thu Sept 25th - #SLI #LCTX #XMTR #VECO #TLS #SEPN #PPSI #ONDS #MASS #IRD #EVAX #IBO #DXLG #CLRB #BTOC #AENT #VOC #SBR #OWLT #INVX #DQ #AMBC - More: crystalequityresearch.com/leading-indi... - #smallcap

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results Septerna (NASDAQ:SEPN) reported Q2 2025 financial results and business updates, highlighting significant progress across its GPCR drug discovery portfolio. The company's cash position stands at $379.2 million, with runway extended into 2029 following a $195 million upfront payment from Novo Nordisk collaboration.Key developments include advancing their PTH1R agonist program for hypoparathyroidism with planned Phase 1 trials in H1 2026, initiating Phase 1 trials for SEP-631 in mast cell diseases in Q3 2025, and progressing their TSHR NAM program for Graves' disease. The company also announced the promotion of Liz Bhatt to President, effective August 1, 2025.Q2 2025 financials showed R&D expenses of $22.2 million and a net loss of $24.8 million, compared to $15.0 million and $16.4 million respectively in Q2 2024.

#SEPN Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/SEPN/septerna-highl...

Septerna Lands Massive $2.2B Novo Nordisk Partnership to Revolutionize Oral Diabetes and Obesity Treatments Landmark $2.2B Novo Nordisk collaboration targets oral metabolic therapies. Strong $398M cash position fuels pipeline advancement. See milestone details.

#SEPN Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/SEPN/septerna-highl...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed May 14th - #SMR #CLSK #QUBT #VLRS #APLD #GENI #RIG #SEPN #ICCT #MLGO #RXRX #RGTI #QBTS #ONDS #LUNR #IXHL #IDR #HL #RUN #ASST - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Breaking News: ( NASDAQ: #SEPN ) Novo Nordisk and Septerna Partner to Develop Oral Small Molecule Therapies for Obesity and Cardiometabolic Diseases

Septerna Discontinues Key Drug Trial: What's Next for $420M Biotech Pipeline? Key PTH1R program discontinued amid safety concerns, but $420.8M cash runway extends to 2028. New MRGPRX2 candidate advancing to clinic in 2025.

#SEPN Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/SEPN/septerna-provi...

Pomerantz Law Firm Launches Investigation Into Septerna, Inc. Amid Potential Securities Fraud Claims Pomerantz Law Firm is probing claims against Septerna, Inc. for possible securities fraud following its stock price plunge after pausing a clinical trial.

Pomerantz Law Firm Launches Investigation Into Septerna, Inc. Amid Potential Securities Fraud Claims #United_States #New_York #Pomerantz #SEPN #Septerna

Pomerantz Law Firm Investigates Potential Securities Fraud at Septerna, Inc. Following Clinical Trial Discontinuation Pomerantz LLP is probing claims from investors in Septerna, Inc. due to possible securities fraud surrounding halted clinical trials.

Pomerantz Law Firm Investigates Potential Securities Fraud at Septerna, Inc. Following Clinical Trial Discontinuation #United_States #New_York #Pomerantz_LLP #Septerna_Inc #SEPN

Just In: ( NASDAQ: #SEPN ) Expected earnings - Septerna Inc.

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Tue Feb 18th - #TRS #CATO #JELD #KUKE #RCUS #SAR #BPTH #CISO #EGBN #FORA #GLDD #SEPN #SUNE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Urgent Update: Septerna Ends Key Clinical Trial, Reveals $440M War Chest for Next-Gen Drug Septerna discontinues SEP-786 trial after bilirubin concerns, shifts focus to advancing next-generation PTH1R agonists with $440M cash runway through 2027.

#SEPN Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

www.stocktitan.net/news/SEPN/septerna-annou...

#SEPN Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/SEPN/septerna-repor...